Journal of AIDS & Clinical Research

MA Julie Westerink

Publications

• Research Article
  Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults
  Author(s): Jennifer A Ohtola, Jessica L Saul-McBeth, Anita S Iyer, David J Leggat, Sadik A Khuder, Noor M Khaskhely and MA Julie WesterinkJennifer A Ohtola, Jessica L Saul-McBeth, Anita S Iyer, David J Leggat, Sadik A Khuder, Noor M Khaskhely and MA Julie Westerink
  
  Background: The number of aging human immunodeficiency virus-infected (HIV+) individuals living in the United States has substantially grown over the past two decades. Advanced age and HIV infection both increase susceptibility to Streptococcus pneumoniae infection due to B cell dysfunction. The combined impact of these factors on pneumococcal vaccine responses remains unknown. Methods: We assessed serum immunoglobulin (Ig) G and IgM levels and opsonophagocytic killing assay (OPA) titers to pneumococcal serotypes 14 and 23F in HIV+ subjects and HIV-uninfected (HIV–) controls 50-65 years old. HIV+ individuals with CD4+ T cells/μl (CD4) >200 and ≥1 year of antiretroviral therapy (ART) received either a dose of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine 8 weeks later.. Read More»
  DOI: 10.4172/2155-6113.1000556

  Abstract PDF